Liver cancer is the second most common cause of cancer death worldwide. Researchers from Mayo Clinic and Exact Sciences Corporation have developed a simple blood test using abnormal DNA markers that are known to exist in liver cancer tissues. A phase II study for this test has been completed. The next step is to validate the markers in blood testing on larger patient cohorts.
“We were most excited that our DNA markers were able to detect more than 90 percent of patients with curable stage tumors,” says John Kisiel, M.D. “This is the main reason why we think a DNA test will make difference, compared to currently available tests.”
Share the news about this research to spread the word to those who may need it.
As a leading institution funded by the National Cancer Institute, Mayo Clinic Cancer Center conducts basic, clinical and population science research, translating discoveries into improved methods for prevention, diagnosis, prognosis and therapy. Learn more about clinical trials for cancer.
Send an email to invite people you know to join the Mayo Clinic Champions page.